MX392706B - Ensayo a base de células para detectar homodímeros anti-cd3. - Google Patents
Ensayo a base de células para detectar homodímeros anti-cd3.Info
- Publication number
- MX392706B MX392706B MX2017015011A MX2017015011A MX392706B MX 392706 B MX392706 B MX 392706B MX 2017015011 A MX2017015011 A MX 2017015011A MX 2017015011 A MX2017015011 A MX 2017015011A MX 392706 B MX392706 B MX 392706B
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- homodimers
- based assay
- detecting anti
- tdb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Eye Examination Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167761P | 2015-05-28 | 2015-05-28 | |
| PCT/US2016/034868 WO2016191750A1 (en) | 2015-05-28 | 2016-05-27 | Cell-based assay for detecting anti-cd3 homodimers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017015011A MX2017015011A (es) | 2018-03-23 |
| MX392706B true MX392706B (es) | 2025-03-24 |
Family
ID=56236065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015011A MX392706B (es) | 2015-05-28 | 2016-05-27 | Ensayo a base de células para detectar homodímeros anti-cd3. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10690678B2 (enExample) |
| EP (2) | EP3795679A1 (enExample) |
| JP (1) | JP6810058B2 (enExample) |
| KR (1) | KR102583058B1 (enExample) |
| CN (1) | CN107646038B (enExample) |
| AU (1) | AU2016267691B2 (enExample) |
| CA (1) | CA2987403A1 (enExample) |
| ES (1) | ES2823033T3 (enExample) |
| HR (1) | HRP20201779T1 (enExample) |
| IL (1) | IL255696B (enExample) |
| MX (1) | MX392706B (enExample) |
| SG (1) | SG10201911335TA (enExample) |
| SI (1) | SI3303400T1 (enExample) |
| WO (1) | WO2016191750A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| MA40579A (fr) | 2014-09-12 | 2016-03-17 | Genentech Inc | Anticorps anti-cll-1 et immunoconjugués |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| DK3310814T5 (da) | 2015-06-16 | 2024-10-07 | Hoffmann La Roche | Humaniserede og affinitetsmodnede antistoffer mod FcRH5 og fremgangsmåder til anvendelse |
| CN109073635A (zh) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于测定t细胞依赖性双特异性抗体的方法 |
| JP7784795B2 (ja) | 2016-11-15 | 2025-12-12 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与 |
| WO2018108759A1 (en) * | 2016-12-13 | 2018-06-21 | F. Hoffmann-La Roche Ag | Method to determine the presence of a target antigen in a tumor sample |
| IL325995A (en) | 2018-02-08 | 2026-03-01 | Genentech Inc | Bispecific antigen binding molecules and methods of use |
| CN108918892B (zh) * | 2018-08-01 | 2021-04-27 | 百奥泰生物制药股份有限公司 | 一种测定抗vegf抗体活性的方法及其应用 |
| TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
| CN111077311B (zh) * | 2019-12-30 | 2023-05-09 | 北京立康生命科技有限公司 | 一种酶联免疫斑点检测试剂盒及其检测方法 |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
| AU2021374594B2 (en) | 2020-11-04 | 2026-03-05 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| TWI874719B (zh) | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
| JP7716473B2 (ja) | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| CN112458149B (zh) * | 2020-12-03 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法 |
| CN112921004B (zh) * | 2021-02-05 | 2023-08-08 | 上海精翰生物科技有限公司 | 用于cd3受体激动剂检测的细胞株及其构建方法及cd3受体激动剂检测方法 |
| EP4337330A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2023250485A1 (en) | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| WO1993016177A1 (en) | 1992-02-11 | 1993-08-19 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US8372954B2 (en) | 2000-12-22 | 2013-02-12 | National Research Council Of Canada | Phage display libraries of human VH fragments |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HRP20201779T1 (hr) | 2015-05-28 | 2021-01-22 | Genentech, Inc. | Stanični test za otkrivanje anti-cd3 homodimera |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CN109073635A (zh) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于测定t细胞依赖性双特异性抗体的方法 |
-
2016
- 2016-05-27 HR HRP20201779TT patent/HRP20201779T1/hr unknown
- 2016-05-27 JP JP2017561777A patent/JP6810058B2/ja active Active
- 2016-05-27 EP EP20190490.1A patent/EP3795679A1/en not_active Withdrawn
- 2016-05-27 ES ES16732377T patent/ES2823033T3/es active Active
- 2016-05-27 CA CA2987403A patent/CA2987403A1/en active Pending
- 2016-05-27 AU AU2016267691A patent/AU2016267691B2/en active Active
- 2016-05-27 SG SG10201911335TA patent/SG10201911335TA/en unknown
- 2016-05-27 EP EP16732377.3A patent/EP3303400B1/en active Active
- 2016-05-27 SI SI201631004T patent/SI3303400T1/sl unknown
- 2016-05-27 MX MX2017015011A patent/MX392706B/es unknown
- 2016-05-27 KR KR1020177036974A patent/KR102583058B1/ko active Active
- 2016-05-27 CN CN201680030308.8A patent/CN107646038B/zh active Active
- 2016-05-27 WO PCT/US2016/034868 patent/WO2016191750A1/en not_active Ceased
-
2017
- 2017-11-15 IL IL255696A patent/IL255696B/en unknown
- 2017-11-28 US US15/824,992 patent/US10690678B2/en active Active
-
2020
- 2020-05-14 US US16/874,550 patent/US12007398B2/en active Active
-
2024
- 2024-04-16 US US18/636,947 patent/US20240280586A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL255696A (en) | 2018-01-31 |
| EP3303400B1 (en) | 2020-09-09 |
| AU2016267691B2 (en) | 2022-06-16 |
| MX2017015011A (es) | 2018-03-23 |
| US20180267055A1 (en) | 2018-09-20 |
| HRP20201779T1 (hr) | 2021-01-22 |
| IL255696B (en) | 2022-04-01 |
| WO2016191750A1 (en) | 2016-12-01 |
| EP3795679A1 (en) | 2021-03-24 |
| SI3303400T1 (sl) | 2021-01-29 |
| HK1250045A1 (zh) | 2018-11-23 |
| KR20180013986A (ko) | 2018-02-07 |
| SG10201911335TA (en) | 2020-01-30 |
| US12007398B2 (en) | 2024-06-11 |
| EP3303400A1 (en) | 2018-04-11 |
| CN107646038B (zh) | 2021-08-20 |
| ES2823033T3 (es) | 2021-05-05 |
| CN107646038A (zh) | 2018-01-30 |
| CA2987403A1 (en) | 2016-12-01 |
| AU2016267691A1 (en) | 2017-12-21 |
| US20240280586A1 (en) | 2024-08-22 |
| JP6810058B2 (ja) | 2021-01-06 |
| JP2018521635A (ja) | 2018-08-09 |
| US20200378987A1 (en) | 2020-12-03 |
| KR102583058B1 (ko) | 2023-09-25 |
| BR112017025051A2 (pt) | 2018-08-07 |
| US10690678B2 (en) | 2020-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392706B (es) | Ensayo a base de células para detectar homodímeros anti-cd3. | |
| MX2017003790A (es) | Detección de secuencias diana por percepción de nanoporos de sondas sintéticas. | |
| MX373248B (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
| BR112014025384A8 (pt) | método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares | |
| MX383381B (es) | Métodos y composiciones para detectar proteínas mal plegadas. | |
| MX380519B (es) | Métodos, kits y aparato para expandir una población de células. | |
| GB2556004A (en) | Markers of stroke and stroke severity | |
| MX2017005750A (es) | Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso. | |
| BR112015022490A2 (pt) | métodos e composições para classificação de amostras | |
| EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
| WO2014186761A3 (en) | Methods for determining responsiveness to an anti-cd47 agent | |
| BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
| BR112017022329A2 (pt) | métodos para detectar aglutinação e composições para uso na prática do mesmo | |
| MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
| WO2017050939A3 (en) | Method and array for diagnosing pancreatic cancer in an individual | |
| BR112015019567A8 (pt) | inibidor de wnt, seu uso e métodos para prognosticar sensibilidade ao mesmo, e composição farmacêutica | |
| GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms | |
| MX2017007232A (es) | Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. | |
| MX2017001134A (es) | Composiciones y metodos para la deteccion y analisis de tuberculosis micobacteriana. | |
| WO2015189591A3 (en) | Method and arrays for use in diagnosing early breast cancer | |
| BR112018001256A2 (pt) | método de ensaio para avaliação de uma ou mais subclasses de células sanguíneas de interesse (bcoi), método para avaliar a quantidade de receptores de cd4 localizados nas superfícies de células cd4+ e opcionalmente, para avaliar a quantidade de receptores de cd8 localizados nas superfícies de células, dispositivo de ensaio de fluxo vertical para realizar um método, e, uso de um dispositivo. | |
| MX374601B (es) | Procedimientos y series para su uso en los mismos. | |
| MX2017010505A (es) | Inmunoensayo homogeneo con compensacion para señal de fondo. | |
| MX378728B (es) | Ensayo de inflamacion oral. | |
| CL2020002715A1 (es) | Composiciones y métodos para tratar la endometriosis |